Dr Reddy’s Laboratories has launched Sirolimus tablets 1 mg and 2 mg, a therapeutic equivalent generic version of RAPAMUNE (Sirolimus) tablets in the US market, following the approval by the United States Food & Drug Administration (US FDA).
The RAPAMUNE tablets brand had US sales of approximately $206 million MAT for the most recent twelve months ending in August 2014 according to IMS Health.
Dr Reddy’s Sirolimus tablets in 1 mg and 2 mg are available in bottle counts of 100.
EP News Bureau –Mumbai
